Let's hunt...Venus Concept Inc. (NASDAQ: VERO): A Troubled Aesthetic Device Company with Insider Red Flags
Ticker: VERO Mkt Cap & EV:4.4M Sector: Medical Devices –Current Price: $3.18 (post 1-for-11 reverse split) Latest Reverse Split: 1-for-11 effective March 3, 2025
Regulatory Scrutiny in China?
In 2019, Venus Concept's Chinese subsidiary faced investigations by the Xuhui and Huangpu branches of the State Administration for Market Regulation (SAMR) concerning the classification of its Versa device. The issue centered on whether the device was improperly sold as a non-medical device. The company ceased sales of the product in China and accepted a nominal penalty of approximately $150 in 2021
Insiders Dumping Shares, Business Divesting, Reverse Splitting to Survive
We believe Venus Concept is in the final phase of value destruction.
Insiders are exiting. The core business is shrinking. Management is selling assets and executing reverse splits to stay listed. The red flags here are too many to ignore.
Executive Summary
Venus Concept is a cosmetic-device manufacturer focused on aesthetic solutions (e.g., Venus Legacy, Venus Versa).
The company has lost over 90% of its equity value in the last 24 months.
Debt Restructuring - In an effort to regain NASDAQ compliance, Venus Concept executed a $35 million debt-to-equity transaction in May 2024. This move temporarily boosted the stock price, which soared by 127% in pre-market trading following the announcement.
In March 2025, Venus implemented a 1-for-11 reverse split to avoid delisting.
Leadership Changes - In December 2024,Dr. Garheng Kong resigned from the company's board of directors and the Nominating and Corporate Governance Committee.
In June 2025, it sold its Venus Hair business—once considered a growth vertical—for $20M cash, reduce operation expense by eliminating a cash-burring division.
Multiple insiders, including board members, have executed repeated stock sales throughout the past year, with zero reported purchases.
The Business Is Contracting
Venus Concept markets itself as a global leader in aesthetic medical devices. Yet:
Revenue has fallen sharply, from $17.46M in Q1 2024 to $13.64M in Q1 2025, a drop of nearly 22%.
Gross margin fell to 42.3%, compared to 44.9% a year earlier.
Operating losses widened to $12.4M in the latest quarter.
Cash reserves have dropped to just $4.8M, while the company carries $78M in debt.
"This is a company burning cash, selling pieces of itself, and hoping reverse splits will keep it in the game."
Source: Q1 2025 Financials – GlobeNewswire
The Reverse Split: A Desperate Move
On March 3, 2025, VERO completed a 1-for-11 reverse stock split.
This move followed an extended period where the stock traded below $0.30, risking delisting by NASDAQ.
While management claimed this was to improve “investor perception,” the stock has since fallen again—a typical result of cosmetic price manipulation rather than fundamental improvement.
Source: NASDAQ Announcement
Insiders Have Been Selling – Not Buying
Insider trading data tells a sobering story:
Here’s a breakdown of recent trading of $VERO stock by insiders over the last 6 months:
Director Anthony Natale sold 42,768 shares on May 10, 2024, with no purchases since.
Michael Willingham has executed 22 separate sell transactions, totaling 796,083 shares.
No executive or board member has reported any open-market purchases during this time.
“When the people closest to the company don’t want the stock, why should anyone else?”
Source: QuiverQuant Insider Trades – VERO
The Venus Hair Divestiture – Selling Off the Furniture
On June 6, 2025, Venus announced the sale of its “Venus Hair” business to Meta Healthcare for $20 million cash.
The hair division, once considered a long-term growth asset, had been underperforming:
Only ~$12.5M in annual revenue
$6.7M in operating cash burn in 2024
"When growth becomes a liability, the company is forced to sell not by strategy—but by necessity."
Sources:
Capital Raise? Or Just Delay?
The company also raised $1.15M in a direct offering in June 2025—a paltry amount considering its liabilities.
With nearly $80M in long-term debt and consistent cash burn, future dilution seems inevitable.
Source: GuruFocus Coverage
Final Thoughts
Venus Concept exhibits the classic profile of a deteriorating small-cap:
👉China insiders
👉 Reverse splits to remain listed
👉 Insider exits
👉 Fire-sale divestitures
👉 Shrinking revenues and expanding losses
These facts speak louder than any pitch deck or earnings call. Investors should draw their own conclusions.
Disclaimer: This is general information only and not financial advice. For personal guidance, please talk to a licensed professional.